Endogenous retroviral proteins provide an immunodominant but not requisite antigen in a murine immunotherapy tumor model

Clinical observations suggest that responses to cancer immunotherapy are correlated with intra-tumoral T cell receptor (TCR) clonality, tumor mutation burden (TMB) and host HLA genotype, highlighting the importance of host T cell recognition of tumor antigens. However, the dynamic interplay between...

Full description

Saved in:
Bibliographic Details
Published inOncoimmunology Vol. 9; no. 1; p. 1758602
Main Authors Ye, Xuan, Waite, Janelle C., Dhanik, Ankur, Gupta, Namita, Zhong, Maggie, Adler, Christina, Malahias, Evangelia, Ni, Min, Wei, Yi, Gurer, Cagan, Zhang, Wen, Macdonald, Lynn E., Murphy, Andrew J., Sleeman, Matthew A., Skokos, Dimitris
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 01.01.2020
Taylor & Francis Group
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Clinical observations suggest that responses to cancer immunotherapy are correlated with intra-tumoral T cell receptor (TCR) clonality, tumor mutation burden (TMB) and host HLA genotype, highlighting the importance of host T cell recognition of tumor antigens. However, the dynamic interplay between T cell activation state and changes in TCR repertoire in driving the identification of potential immunodominant antigen(s) remains largely unexplored. Here, we performed single-cell RNA-sequencing on CD8 + tumor-infiltrating T cells (TILs) using the murine colorectal tumor model MC38 to identify unique TCR sequences and validate their tumor reactivity. We found that the majority of clonally expanded TILs are tumor-reactive and their TCR repertoire is unique amongst individual MC38 tumor-bearing mice. Our query identified that multiple expanded TCR clones recognized the retroviral epitope p15E as an immunodominant antigen. In addition, we found that the endogenous retroviral genome encoding for p15E is highly expressed in MC38 tumors, but not in normal tissues, due to epigenetic derepression. Further, we demonstrated that the p15E-specific TILs exhibit an activated phenotype and an increase in frequency upon treatment with anti-41BB and anti-PD-1 combination immunotherapy. Importantly, we showed that although p15E-specific TILs are not required to mount a primary anti-tumor response, they contributed to the development of strong immune memory. Overall our results revealed that endogenous retroviral antigens expressed by tumor cells may represent an important and underappreciated category of tumor antigens that could be readily targeted in the clinic.
AbstractList Clinical observations suggest that responses to cancer immunotherapy are correlated with intra-tumoral T cell receptor (TCR) clonality, tumor mutation burden (TMB) and host HLA genotype, highlighting the importance of host T cell recognition of tumor antigens. However, the dynamic interplay between T cell activation state and changes in TCR repertoire in driving the identification of potential immunodominant antigen(s) remains largely unexplored. Here, we performed single-cell RNA-sequencing on CD8 + tumor-infiltrating T cells (TILs) using the murine colorectal tumor model MC38 to identify unique TCR sequences and validate their tumor reactivity. We found that the majority of clonally expanded TILs are tumor-reactive and their TCR repertoire is unique amongst individual MC38 tumor-bearing mice. Our query identified that multiple expanded TCR clones recognized the retroviral epitope p15E as an immunodominant antigen. In addition, we found that the endogenous retroviral genome encoding for p15E is highly expressed in MC38 tumors, but not in normal tissues, due to epigenetic derepression. Further, we demonstrated that the p15E-specific TILs exhibit an activated phenotype and an increase in frequency upon treatment with anti-41BB and anti-PD-1 combination immunotherapy. Importantly, we showed that although p15E-specific TILs are not required to mount a primary anti-tumor response, they contributed to the development of strong immune memory. Overall our results revealed that endogenous retroviral antigens expressed by tumor cells may represent an important and underappreciated category of tumor antigens that could be readily targeted in the clinic.
Clinical observations suggest that responses to cancer immunotherapy are correlated with intra-tumoral T cell receptor (TCR) clonality, tumor mutation burden (TMB) and host HLA genotype, highlighting the importance of host T cell recognition of tumor antigens. However, the dynamic interplay between T cell activation state and changes in TCR repertoire in driving the identification of potential immunodominant antigen(s) remains largely unexplored. Here, we performed single-cell RNA-sequencing on CD8 tumor-infiltrating T cells (TILs) using the murine colorectal tumor model MC38 to identify unique TCR sequences and validate their tumor reactivity. We found that the majority of clonally expanded TILs are tumor-reactive and their TCR repertoire is unique amongst individual MC38 tumor-bearing mice. Our query identified that multiple expanded TCR clones recognized the retroviral epitope p15E as an immunodominant antigen. In addition, we found that the endogenous retroviral genome encoding for p15E is highly expressed in MC38 tumors, but not in normal tissues, due to epigenetic derepression. Further, we demonstrated that the p15E-specific TILs exhibit an activated phenotype and an increase in frequency upon treatment with anti-41BB and anti-PD-1 combination immunotherapy. Importantly, we showed that although p15E-specific TILs are not required to mount a primary anti-tumor response, they contributed to the development of strong immune memory. Overall our results revealed that endogenous retroviral antigens expressed by tumor cells may represent an important and underappreciated category of tumor antigens that could be readily targeted in the clinic.
Clinical observations suggest that responses to cancer immunotherapy are correlated with intra-tumoral T cell receptor (TCR) clonality, tumor mutation burden (TMB) and host HLA genotype, highlighting the importance of host T cell recognition of tumor antigens. However, the dynamic interplay between T cell activation state and changes in TCR repertoire in driving the identification of potential immunodominant antigen(s) remains largely unexplored. Here, we performed single-cell RNA-sequencing on CD8+ tumor-infiltrating T cells (TILs) using the murine colorectal tumor model MC38 to identify unique TCR sequences and validate their tumor reactivity. We found that the majority of clonally expanded TILs are tumor-reactive and their TCR repertoire is unique amongst individual MC38 tumor-bearing mice. Our query identified that multiple expanded TCR clones recognized the retroviral epitope p15E as an immunodominant antigen. In addition, we found that the endogenous retroviral genome encoding for p15E is highly expressed in MC38 tumors, but not in normal tissues, due to epigenetic derepression. Further, we demonstrated that the p15E-specific TILs exhibit an activated phenotype and an increase in frequency upon treatment with anti-41BB and anti-PD-1 combination immunotherapy. Importantly, we showed that although p15E-specific TILs are not required to mount a primary anti-tumor response, they contributed to the development of strong immune memory. Overall our results revealed that endogenous retroviral antigens expressed by tumor cells may represent an important and underappreciated category of tumor antigens that could be readily targeted in the clinic.
Author Waite, Janelle C.
Murphy, Andrew J.
Sleeman, Matthew A.
Dhanik, Ankur
Wei, Yi
Ni, Min
Adler, Christina
Skokos, Dimitris
Macdonald, Lynn E.
Malahias, Evangelia
Ye, Xuan
Gupta, Namita
Zhong, Maggie
Zhang, Wen
Gurer, Cagan
Author_xml – sequence: 1
  givenname: Xuan
  surname: Ye
  fullname: Ye, Xuan
  organization: Regeneron Pharmaceuticals
– sequence: 2
  givenname: Janelle C.
  surname: Waite
  fullname: Waite, Janelle C.
  email: Janelle.waite@regeneron.com
  organization: Regeneron Pharmaceuticals
– sequence: 3
  givenname: Ankur
  surname: Dhanik
  fullname: Dhanik, Ankur
  organization: Regeneron Pharmaceuticals
– sequence: 4
  givenname: Namita
  surname: Gupta
  fullname: Gupta, Namita
  organization: Regeneron Pharmaceuticals
– sequence: 5
  givenname: Maggie
  surname: Zhong
  fullname: Zhong, Maggie
  organization: Regeneron Pharmaceuticals
– sequence: 6
  givenname: Christina
  surname: Adler
  fullname: Adler, Christina
  organization: Regeneron Pharmaceuticals
– sequence: 7
  givenname: Evangelia
  surname: Malahias
  fullname: Malahias, Evangelia
  organization: Regeneron Pharmaceuticals
– sequence: 8
  givenname: Min
  surname: Ni
  fullname: Ni, Min
  organization: Regeneron Pharmaceuticals
– sequence: 9
  givenname: Yi
  surname: Wei
  fullname: Wei, Yi
  organization: Regeneron Pharmaceuticals
– sequence: 10
  givenname: Cagan
  surname: Gurer
  fullname: Gurer, Cagan
  organization: Regeneron Pharmaceuticals
– sequence: 11
  givenname: Wen
  surname: Zhang
  fullname: Zhang, Wen
  organization: Regeneron Pharmaceuticals
– sequence: 12
  givenname: Lynn E.
  surname: Macdonald
  fullname: Macdonald, Lynn E.
  organization: Regeneron Pharmaceuticals
– sequence: 13
  givenname: Andrew J.
  surname: Murphy
  fullname: Murphy, Andrew J.
  organization: Regeneron Pharmaceuticals
– sequence: 14
  givenname: Matthew A.
  surname: Sleeman
  fullname: Sleeman, Matthew A.
  organization: Regeneron Pharmaceuticals
– sequence: 15
  givenname: Dimitris
  surname: Skokos
  fullname: Skokos, Dimitris
  email: dimitris.skokos@regeneron.com
  organization: Regeneron Pharmaceuticals
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32923116$$D View this record in MEDLINE/PubMed
BookMark eNp9Uk1v1DAUtFARLaU_AeQjly3-ipNcEKgqUKkSF5C4WY79snUV21vb2bL_HofdrugFX2y9NzPvyTOv0UmIARB6S8klJR35wKhkgrBfl4ywWmqbThL2Ap0t9dXSODm-KT1FFznfk3okaSTvX6FTznrGKZVn6Pd1sHENIc4ZJygpbl3SE96kWMCFvDy2zgLWATvv5xBt9C7oUPAwFxxiqayH2WVXFkxxVQq7gDX2c3IBDqRyB0lvdrjMPibso4XpDXo56inDxeE-Rz-_XP-4-ra6_f715urz7co0XJSV5T1rhDYtp43ph3ZoWwaEt8CBaiv4AC0ZJB0ptWRgcuyJBgDW9HKQgneCn6Obva6N-l5tkvM67VTUTv0txLRWOhVnJlDQAKGy67WRjaAgOyF0VSCGEM6NHKrWx73WZh48WAOh1M96Jvq8E9ydWsetakV1iNIq8P4gkOLDDLko77KBadIBqgOKCVFXr3b2FdrsoSbFnBOMxzGUqCUE6ikEagmBOoSg8t79u-OR9WR5BXzaA1wYY_L6MabJqqJ3U0xj0sG4rPj_Z_wBrezF0A
CitedBy_id crossref_primary_10_1080_2162402X_2021_1958589
crossref_primary_10_1371_journal_pone_0248903
crossref_primary_10_1158_1078_0432_CCR_20_3701
crossref_primary_10_3389_fimmu_2022_886683
crossref_primary_10_1136_jitc_2023_008001
crossref_primary_10_1158_2326_6066_CIR_21_0831
crossref_primary_10_1172_JCI171621
crossref_primary_10_1038_s41586_021_03994_2
crossref_primary_10_1158_2767_9764_CRC_23_0384
crossref_primary_10_1038_s42003_020_1083_1
crossref_primary_10_1136_jitc_2021_003721
Cites_doi 10.1111/imr.12614
10.1038/nature13954
10.1128/JVI.49.2.471-478.1984
10.1158/0008-5472.CAN-07-6838
10.1038/35074122
10.1007/s00018-011-0657-y
10.4049/jimmunol.1302972
10.1038/nature22991
10.1172/JCI73639
10.1158/0008-5472.1089.65.3
10.1126/science.aao4572
10.1158/2326-6066.CIR-17-0489
10.1038/srep41960
10.1097/00002371-200003000-00001
10.1186/1471-2164-9-225
10.1093/jnci/djr540
10.1002/ijc.22256
10.3389/fimmu.2018.01638
10.1038/nature12477
10.3389/fmicb.2018.00462
10.1002/hep.30091
10.1126/science.1840703
10.1158/1078-0432.CCR-13-2648
10.4049/jimmunol.162.2.989
10.1038/s41591-018-0266-5
10.1038/nm.4051
10.1126/sciimmunol.aat7061
10.1158/2326-6066.CIR-16-0060
10.1038/nrc3670
10.1038/335448a0
10.1038/cr.2012.1
10.1126/science.7513441
10.1371/journal.pone.0207020
10.1146/annurev-virology-031413-085537
10.1158/0008-5472.CAN-17-3953
10.3389/fmicb.2018.00178
10.1038/nbt.2938
10.1016/j.cell.2018.05.052
10.1158/1078-0432.CCR-14-3197
10.1038/nature22976
10.4049/jimmunol.152.1.106
10.1038/nri2941
10.1126/sciimmunol.aao4310
10.1080/2162402x.2019.1673125
10.1038/nri3405
10.1002/ijc.11649
10.1038/nature14001
10.1038/nm0697-682
10.1016/j.cell.2017.05.035
10.1073/pnas.92.25.11810
10.1038/s41568-019-0116-x
10.1128/JVI.00646-08
10.4049/jimmunol.1501657
10.1038/nrc2355
10.3389/fimmu.2014.00616
10.1016/j.cell.2017.11.043
10.1158/1078-0432.CCR-14-0388
10.3389/fimmu.2018.01538
10.1158/0008-5472.CAN-17-0236
10.3389/fonc.2013.00180
ContentType Journal Article
Copyright 2020 Regeneron Pharmaceuticals. Published with license by Taylor & Francis Group, LLC. 2020
2020 Regeneron Pharmaceuticals. Published with license by Taylor & Francis Group, LLC.
2020 Regeneron Pharmaceuticals. Published with license by Taylor & Francis Group, LLC. 2020 The Author(s)
Copyright_xml – notice: 2020 Regeneron Pharmaceuticals. Published with license by Taylor & Francis Group, LLC. 2020
– notice: 2020 Regeneron Pharmaceuticals. Published with license by Taylor & Francis Group, LLC.
– notice: 2020 Regeneron Pharmaceuticals. Published with license by Taylor & Francis Group, LLC. 2020 The Author(s)
DBID 0YH
NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.1080/2162402X.2020.1758602
DatabaseName Taylor & Francis Open Access
PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList
PubMed


Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: 0YH
  name: Taylor & Francis Open Access
  url: https://www.tandfonline.com
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Biology
DocumentTitleAlternate X. YE ET AL
EISSN 2162-402X
EndPage 1758602
ExternalDocumentID oai_doaj_org_article_e5e01689ac6541e6844a8430c0033c6b
10_1080_2162402X_2020_1758602
32923116
1758602
Genre Research Article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: Regeneron Pharmaceuticals, Inc
GroupedDBID 00X
0R~
0YH
53G
AAKDD
ABMYL
ABUPF
ACENM
ACGFS
ADBBV
ADCVX
ADFCX
ADING
AENEX
AIJEM
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BABNJ
BLEHA
CCCUG
DGEBU
DGFLZ
EBS
EUPTU
GROUPED_DOAJ
HYE
KRBQP
KSSTO
KTTOD
KWAYT
KYCEM
LJTGL
M4Z
O9-
OK1
RPM
TFL
TFW
UHWXJ
ZA5
H13
NPM
TDBHL
4.4
AAYXX
ABDBF
CITATION
DEAQA
EBD
EJD
OVD
TEORI
TNTFI
TTHFI
7X8
5PM
ID FETCH-LOGICAL-c534t-d39254ac7315c9b7b772e037e3e1ad43be70b61f11d0b26f90aeee2596b643843
IEDL.DBID RPM
ISSN 2162-4011
2162-402X
IngestDate Fri Oct 04 12:58:02 EDT 2024
Tue Sep 17 21:22:29 EDT 2024
Sat Aug 17 02:14:26 EDT 2024
Fri Aug 23 03:06:00 EDT 2024
Tue Aug 27 13:45:51 EDT 2024
Tue Mar 12 04:25:21 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords tumor antigen
TCR
p15E
endogenous retrovirus
single cell sequencing
m8
MC38
Language English
License open-access: http://creativecommons.org/licenses/by-nc/4.0/: This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
2020 Regeneron Pharmaceuticals. Published with license by Taylor & Francis Group, LLC.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c534t-d39254ac7315c9b7b772e037e3e1ad43be70b61f11d0b26f90aeee2596b643843
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458611/
PMID 32923116
PQID 2442597589
PQPubID 23479
PageCount 1
ParticipantIDs crossref_primary_10_1080_2162402X_2020_1758602
pubmed_primary_32923116
proquest_miscellaneous_2442597589
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7458611
informaworld_taylorfrancis_310_1080_2162402X_2020_1758602
doaj_primary_oai_doaj_org_article_e5e01689ac6541e6844a8430c0033c6b
PublicationCentury 2000
PublicationDate 2020-01-01
PublicationDateYYYYMMDD 2020-01-01
PublicationDate_xml – month: 01
  year: 2020
  text: 2020-01-01
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Oncoimmunology
PublicationTitleAlternate Oncoimmunology
PublicationYear 2020
Publisher Taylor & Francis
Taylor & Francis Group
Publisher_xml – name: Taylor & Francis
– name: Taylor & Francis Group
References e_1_3_3_52_1
e_1_3_3_50_1
e_1_3_3_18_1
e_1_3_3_39_1
e_1_3_3_14_1
e_1_3_3_37_1
e_1_3_3_16_1
e_1_3_3_35_1
e_1_3_3_58_1
e_1_3_3_10_1
e_1_3_3_33_1
e_1_3_3_56_1
e_1_3_3_12_1
e_1_3_3_31_1
e_1_3_3_54_1
e_1_3_3_40_1
e_1_3_3_61_1
e_1_3_3_7_1
e_1_3_3_9_1
e_1_3_3_29_1
e_1_3_3_25_1
e_1_3_3_48_1
e_1_3_3_27_1
e_1_3_3_46_1
e_1_3_3_3_1
e_1_3_3_21_1
e_1_3_3_44_1
e_1_3_3_5_1
e_1_3_3_23_1
e_1_3_3_42_1
e_1_3_3_30_1
e_1_3_3_51_1
Kershaw MH (e_1_3_3_47_1) 2001; 61
e_1_3_3_17_1
e_1_3_3_19_1
e_1_3_3_13_1
e_1_3_3_38_1
e_1_3_3_59_1
e_1_3_3_15_1
e_1_3_3_36_1
e_1_3_3_57_1
e_1_3_3_34_1
e_1_3_3_55_1
e_1_3_3_11_1
e_1_3_3_32_1
e_1_3_3_53_1
e_1_3_3_41_1
e_1_3_3_62_1
e_1_3_3_60_1
e_1_3_3_6_1
e_1_3_3_8_1
e_1_3_3_28_1
e_1_3_3_24_1
e_1_3_3_49_1
e_1_3_3_26_1
e_1_3_3_2_1
e_1_3_3_20_1
e_1_3_3_45_1
e_1_3_3_4_1
e_1_3_3_22_1
e_1_3_3_43_1
References_xml – ident: e_1_3_3_43_1
  doi: 10.1111/imr.12614
– ident: e_1_3_3_4_1
  doi: 10.1038/nature13954
– ident: e_1_3_3_35_1
  doi: 10.1128/JVI.49.2.471-478.1984
– ident: e_1_3_3_52_1
  doi: 10.1158/0008-5472.CAN-07-6838
– ident: e_1_3_3_25_1
  doi: 10.1038/35074122
– ident: e_1_3_3_36_1
  doi: 10.1007/s00018-011-0657-y
– ident: e_1_3_3_37_1
  doi: 10.4049/jimmunol.1302972
– volume: 61
  start-page: 7920
  issue: 21
  year: 2001
  ident: e_1_3_3_47_1
  article-title: Immunization against endogenous retroviral tumor-associated antigens
  publication-title: Cancer Res
  contributor:
    fullname: Kershaw MH
– ident: e_1_3_3_22_1
  doi: 10.1038/nature22991
– ident: e_1_3_3_32_1
  doi: 10.1172/JCI73639
– ident: e_1_3_3_26_1
  doi: 10.1158/0008-5472.1089.65.3
– ident: e_1_3_3_5_1
  doi: 10.1126/science.aao4572
– ident: e_1_3_3_15_1
  doi: 10.1158/2326-6066.CIR-17-0489
– ident: e_1_3_3_54_1
  doi: 10.1038/srep41960
– ident: e_1_3_3_29_1
  doi: 10.1097/00002371-200003000-00001
– ident: e_1_3_3_42_1
  doi: 10.1186/1471-2164-9-225
– ident: e_1_3_3_53_1
  doi: 10.1093/jnci/djr540
– ident: e_1_3_3_55_1
  doi: 10.1002/ijc.22256
– ident: e_1_3_3_7_1
  doi: 10.3389/fimmu.2018.01638
– ident: e_1_3_3_3_1
  doi: 10.1038/nature12477
– ident: e_1_3_3_49_1
  doi: 10.3389/fmicb.2018.00462
– ident: e_1_3_3_61_1
  doi: 10.1002/hep.30091
– ident: e_1_3_3_16_1
  doi: 10.1126/science.1840703
– ident: e_1_3_3_10_1
  doi: 10.1158/1078-0432.CCR-13-2648
– ident: e_1_3_3_46_1
  doi: 10.4049/jimmunol.162.2.989
– ident: e_1_3_3_13_1
  doi: 10.1038/s41591-018-0266-5
– ident: e_1_3_3_45_1
  doi: 10.1038/nm.4051
– ident: e_1_3_3_28_1
  doi: 10.1126/sciimmunol.aat7061
– ident: e_1_3_3_30_1
  doi: 10.1158/2326-6066.CIR-16-0060
– ident: e_1_3_3_11_1
  doi: 10.1038/nrc3670
– ident: e_1_3_3_39_1
  doi: 10.1038/335448a0
– ident: e_1_3_3_44_1
  doi: 10.1038/cr.2012.1
– ident: e_1_3_3_18_1
  doi: 10.1126/science.7513441
– ident: e_1_3_3_27_1
  doi: 10.1371/journal.pone.0207020
– ident: e_1_3_3_41_1
  doi: 10.1146/annurev-virology-031413-085537
– ident: e_1_3_3_62_1
  doi: 10.1158/0008-5472.CAN-17-3953
– ident: e_1_3_3_50_1
  doi: 10.3389/fmicb.2018.00178
– ident: e_1_3_3_8_1
  doi: 10.1038/nbt.2938
– ident: e_1_3_3_60_1
  doi: 10.1016/j.cell.2018.05.052
– ident: e_1_3_3_51_1
  doi: 10.1158/1078-0432.CCR-14-3197
– ident: e_1_3_3_23_1
  doi: 10.1038/nature22976
– ident: e_1_3_3_34_1
  doi: 10.4049/jimmunol.152.1.106
– ident: e_1_3_3_6_1
  doi: 10.1038/nri2941
– ident: e_1_3_3_14_1
  doi: 10.1126/sciimmunol.aao4310
– ident: e_1_3_3_21_1
  doi: 10.1080/2162402x.2019.1673125
– ident: e_1_3_3_38_1
  doi: 10.1038/nri3405
– ident: e_1_3_3_58_1
  doi: 10.1002/ijc.11649
– ident: e_1_3_3_20_1
  doi: 10.1038/nature14001
– ident: e_1_3_3_24_1
  doi: 10.1038/nm0697-682
– ident: e_1_3_3_9_1
  doi: 10.1016/j.cell.2017.05.035
– ident: e_1_3_3_17_1
  doi: 10.1073/pnas.92.25.11810
– ident: e_1_3_3_2_1
  doi: 10.1038/s41568-019-0116-x
– ident: e_1_3_3_57_1
  doi: 10.1128/JVI.00646-08
– ident: e_1_3_3_48_1
  doi: 10.4049/jimmunol.1501657
– ident: e_1_3_3_12_1
  doi: 10.1038/nrc2355
– ident: e_1_3_3_40_1
  doi: 10.3389/fimmu.2014.00616
– ident: e_1_3_3_19_1
  doi: 10.1016/j.cell.2017.11.043
– ident: e_1_3_3_56_1
  doi: 10.1158/1078-0432.CCR-14-0388
– ident: e_1_3_3_31_1
  doi: 10.3389/fimmu.2018.01538
– ident: e_1_3_3_33_1
  doi: 10.1158/0008-5472.CAN-17-0236
– ident: e_1_3_3_59_1
  doi: 10.3389/fonc.2013.00180
SSID ssj0000605639
Score 2.3170416
Snippet Clinical observations suggest that responses to cancer immunotherapy are correlated with intra-tumoral T cell receptor (TCR) clonality, tumor mutation burden...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
informaworld
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 1758602
SubjectTerms endogenous retrovirus
MC38
Original Research
p15E
single cell sequencing
TCR
tumor antigen
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3PaxwhFJYQKORSmiZtpz-ChV4nGUdH12NaEkIgPTWwN1HnDZ1D3HbjQvPf96kzYTcUcilzc9RR33P8fPq-R8gXzbgFuRA1852thVC6diI55wxS9NoBiBy15Oa7vLoV18tuuRXqK90JK_TAZeDOoANEJQttfYpYnaoVdiF441MUMi9d_vuybmszVf7BuLBzPbvsLJqzlsl0kLDELWGLSQiT5WRKmRejzNn_hLH0X7jz6fXJrfXo8hV5OQFJel46cEj2ILwmL0poyYcj8uci9KtCwErXEJPhACuhmZZhDPd08sCjNtAxuYjg7rRciqFuE2lYRSz1ezOms2XMExNnJx0DtfQumedhKlS8tx5o3Nyt1jRH1Tkmt5cXP75d1VOUhdp3XMS6R4TUCesVZ53XTjnE29BwBRyY7QV3oBon2cBY37hWDrqxAIC7JukQzaAo3pD9sArwjlCH66C3w9CwgYtBKyc56J6rpnX4CF-R03m4za9CpmHYxFE6y8ck-ZhJPhX5moTymDlxYecE1BAzaYh5TkMqordFamI2hQwlbonhzzTg8yx_g_MuHabYACg6g7AIxwBz6Yq8Lfrw2EzeJtjMZEXUjqbs9GP3TRh_Zm5vJfC7jL3_Hx3_QA5SX4rB6CPZj-sNfEIIFd1Jni1_ARyfF2g
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Taylor & Francis Open Access
  dbid: 0YH
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELZQERIXVN7hJSNxDdix46yPgFqtkOBEpXKy7GQCOdSBXa9E_31n4mTVrUAcUE5J7MTxjOPP45lvGHtjpfJgVrqUbe1LrRtbBk3BOb3RnQ0Aespa8vmLWZ_pT-f14k24nd0qaQ3dZ6KI6V9Ng9uH7eIR966ShvYEznF1V-ElRLyG6CRvVwi9SdXFt_XezCIQruMkvMTu_K32waw0kfffoC79EwC96Ud5bWI6PWb3ZkTJ32cVuM9uQXzA7uQck5cP2e-T2I2ZiZVvIJEFAR_CJ36GIW75HIrHfeQDxYrgMjV7x_CwSzyOCWv92g20yYxlEpF38iFyzy_ITg9zpRzGdcnT7mLc8Cm9ziN2dnry9eO6nNMtlG2tdCo7hEq19m2jZN3a0AQE3iBUAwqk77QK0IhgZC9lJ0Jleis8AODyyQSENSutHrOjOEZ4ynjACbH1fS9kr3Rvm2AU2E41ogp46LZgb5fudj8zq4aTM1npIh9H8nGzfAr2gYSyL0yk2NOFcfPdzWPMQQ0IYFfWt5TcnDRQe2yWaClhXWtCwex1kbo02UT6nMDEqX804PUif4cDkHZVfAQUnUN8hH2ApWzBnmR92DdTVYSfpSlYc6ApB99xeCcOPyaS70bje6V89h9tfs7u0mk2GL1gR2mzg5cIoVJ4NQ2SK-mlFYg
  priority: 102
  providerName: Taylor & Francis
Title Endogenous retroviral proteins provide an immunodominant but not requisite antigen in a murine immunotherapy tumor model
URI https://www.tandfonline.com/doi/abs/10.1080/2162402X.2020.1758602
https://www.ncbi.nlm.nih.gov/pubmed/32923116
https://search.proquest.com/docview/2442597589
https://pubmed.ncbi.nlm.nih.gov/PMC7458611
https://doaj.org/article/e5e01689ac6541e6844a8430c0033c6b
Volume 9
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3di9QwEA-3B4Iv4rf1Y4nga3eTTZo0j3rcsQgnPniwPoUkTbXgpufaBe-_d5K0x-4hCNK3NGmTzrT5zXRmfgi9U5QZL2peUleZknOpSstjck4reKOs9zyxllx-Eusr_nFTbU5QNeXCpKB9Z7tF-LFdhO57iq283rrlFCe2_Hx5JnlVC0qXMzSTjB2Y6PnzC3t6YhBb0XhTUOApc6cmy9gGJtMGLMMVNAFaFiQy2rBVRDqR9fxge0pV_O_UMP0bEr0bUHmwQ108RA9GaInf5yU8Qic-PEb3MtnkzRP0-zw0fS7Jind-iK4EuAhOhRq68AuPOXnYBNzFpBGwV3OYDLb7AYd-gFE_91382wx9hljFE3cBG7yNDns_Dsr5XDd42G_7HU48O0_R1cX5l7N1OfIulK5ifCgbwEwVN04yWjllpQUE7gmTnnlqGs6sl8QK2lLaELsSrSLGew92lLCAb2rOnqHT0Af_AmELO6MzbUtoy3irpBXMq4ZJsrJwcFegxfS49XUur6HpWLV0EpWOotKjqAr0IQrltnOsjp0a-t03PeqI9pUHJFsr4yLLeVRFbmBaxEXmOidsgdShSPWQnCNtZjLR7B8TeDvJX8ObGH-vmOBBdBqAEjwD6KUK9Dzrw-00J_UqkDzSlKN1HJ8B5U_Vvkdlf_nfI1-h-3EB2W_0Gp0Ou71_A0hqsHM0I1_X8-SHmKe36A9DtRym
link.rule.ids 230,315,733,786,790,870,891,2115,27533,27955,27956,53825,53827,59496,59497
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bj9QgFCbrGqMv3i_1iomv7ZRCb4-62c2oOxsfds28EaB0bXToOtLE9dd7gHYzMzExmnmjkIHyUc6Bc74PoTc1oUIXFYuJykXMWFnHkrnknLZgTS21Zl61ZHFSzM_Yh2W-3EP5lAvjg_aV7BLzbZWY7ouPrbxYqdkUJzb7tDgoWV4VhMyuoeuwXrN8w0kPH2DY1b2GWEbc3wKEp9ydKp25MnCaluAbZlAE9nKROk0bmjlbx-meb2xQnsd_h8X0T7bobkjlxh51dAd9nkYXQlO-JoOVifq1Q_z4z8O_i26PVit-Gx7fQ3va3Ec3go7l5QP089A0fWB7xWtt3SkF9A57DojO_MBjuh8WBncuHwVc4RCBg-VgsekttPo-dO4iG-pYRxCKO4MFXrm7AD02Cqlil9gOq36NvYTPQ3R2dHh6MI9HSYdY5ZTZuAFzLGdClZTkqpalBONep7TUVBPRMCp1mcqCtIQ0qcyKtk6F1hpctEKC6VQx-gjtm97oJwhL2HSVaNuUtJS1dSkLquuGlmkm4cdUhJJpHvlFYO7gZCREnTDAHQb4iIEIvXOzfVXZEW_7gn59zsf3z3WuwUiuaqGcgLpDORPQrVQ5UTxVyAjVm1jh1p-7tEEkhdO_dOD1BCwOi9zd3AijYeo42GDwDqBWHaHHAWhX3ZxwG6FyC4Jb49h-AsDyROIjkJ7-d8tX6Ob8dHHMj9-ffHyGbrnBhOOp52jfrgf9Agw2K1_65fkbNjA8tQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9QwFLagCMSFnRJWI3HN4tjZjlA6KkurHqg04mLZjgMRHWcYEony63m2kyozQkKq5uaxFTv-HH_Pfu99CL2pCBU6L1lIVCZCxooqlMwG5zQ5qyupNXOqJccn-dEZ-7jMljOpL-e0r2QbmfNVZNrvzrdyvVLx5CcWnx4fFCwrc0Lidd3E19ENWLNpMTPU_UcYdnanI5YS-2iA8RS_UyaxLQPDaQn2YQpFwJnzxOra0NTyHat9PtukXC7_nUym_-Kju26Vs31qcRd9nUbo3VN-REMvI_VnJ_njlV7BPXRnZK_4ra9yH13T5gG66fUsLx6i34em7nzWV7zRvT2tgB5ilwuiNb_wGPaHhcGtjUsBk9h74mA59Nh0PbT6ObT2Qhvq9DZRKG4NFnhl7wT02MiHjF3gflh1G-ykfB6hs8Xhl4OjcJR2CFVGWR_WQMsyJlRBSaYqWUgg-TqhhaaaiJpRqYtE5qQhpE5kmjdVIrTWYKrlEihUyehjtGc6o58gLGHzVaJpEtJQ1lSFzKmualokqYQfUwGKprnka5_Bg5MxMeqEA25xwEccBOidnfHLyjYBtyvoNt_4OAdcZxrIclkJZYXULdqZgG4lyorjqVwGqJrjhffu_KXxYimc_qcDrydwcVjs9gZHGA1Tx4GLwTuAWlWA9j3YLrs5YTdAxRYMt8ax_Q-AyyUUH8H09MotX6Fbp-8X_POHk0_P0G07Fn9K9Rzt9ZtBvwDe1suXboX-BRwvPzU
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Endogenous+retroviral+proteins+provide+an+immunodominant+but+not+requisite+antigen+in+a+murine+immunotherapy+tumor+model&rft.jtitle=Oncoimmunology&rft.au=Ye%2C+Xuan&rft.au=Waite%2C+Janelle+C&rft.au=Dhanik%2C+Ankur&rft.au=Gupta%2C+Namita&rft.date=2020-01-01&rft.issn=2162-4011&rft.volume=9&rft.issue=1&rft.spage=1758602&rft_id=info:doi/10.1080%2F2162402X.2020.1758602&rft_id=info%3Apmid%2F32923116&rft.externalDocID=32923116
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2162-4011&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2162-4011&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2162-4011&client=summon